Methotrexate Disodium

This article explores the use of Methotrexate Disodium in clinical trials for various medical conditions. Methotrexate Disodium is being studied as a treatment option for conditions such as psoriatic arthritis, non-infectious uveitis, and primary central nervous system lymphoma. The trials aim to evaluate its effectiveness, safety, and potential combinations with other drugs to improve patient outcomes.

Table of Contents

Introduction

Methotrexate Disodium is a widely used medication that plays a crucial role in treating various medical conditions. This article aims to provide patients with a comprehensive understanding of this drug, its uses, benefits, and potential risks.

What is Methotrexate Disodium?

Methotrexate Disodium is a medication that belongs to a class of drugs known as antimetabolites[1]. It works by interfering with the growth of certain cells in the body, particularly those that multiply quickly. This mechanism of action makes it effective in treating various conditions, including certain types of cancer and autoimmune disorders.

Medical Conditions Treated

Methotrexate Disodium is used to treat a wide range of medical conditions, including:

  • Rheumatoid Arthritis: A chronic inflammatory disorder affecting the joints[2]
  • Psoriatic Arthritis: A form of arthritis that affects some people with psoriasis[3]
  • Hypophosphatasia: A rare genetic disorder affecting bone and tooth development[1]
  • Primary CNS Lymphoma: A type of cancer that starts in the brain or spinal cord[4]
  • Non-infectious Uveitis: Inflammation of the middle layer of the eye[5]

Administration and Dosage

Methotrexate Disodium can be administered in various forms, including:

  • Oral tablets
  • Subcutaneous injections
  • Intravenous infusions

The dosage and administration method depend on the specific condition being treated, the patient’s age, weight, and overall health status. For example:

  • For rheumatoid arthritis, a typical oral dose might range from 7.5 to 25 mg once weekly[2]
  • For primary CNS lymphoma, higher doses of up to 3.5 g/m² may be given intravenously[4]

It’s crucial for patients to follow their doctor’s instructions precisely and never adjust the dosage without medical supervision.

Efficacy and Benefits

Methotrexate Disodium has shown significant efficacy in treating various conditions:

  • In rheumatoid and psoriatic arthritis, it can help reduce joint pain, swelling, and slow disease progression[2][3]
  • For hypophosphatasia, it may help improve bone mineralization when used in combination with other treatments[1]
  • In primary CNS lymphoma, it forms a crucial part of chemotherapy regimens, helping to target cancer cells[4]
  • For non-infectious uveitis, it can help control inflammation and prevent vision loss[5]

Potential Side Effects

While Methotrexate Disodium can be highly effective, it may cause side effects. Common side effects include:

  • Nausea and vomiting
  • Fatigue
  • Mouth sores
  • Headache
  • Dizziness
  • Hair loss

More serious side effects, though less common, may include:

  • Liver damage
  • Lung problems
  • Bone marrow suppression
  • Increased risk of infections

It’s important to report any side effects to your healthcare provider promptly.

Precautions and Contraindications

Methotrexate Disodium is not suitable for everyone. It should not be used in patients with:

  • Pregnancy or breastfeeding
  • Severe liver or kidney disease
  • Active infections
  • Certain blood disorders

Additionally, patients taking Methotrexate Disodium should avoid alcohol and certain medications that may interact with it. Regular blood tests are typically required to monitor liver function and blood cell counts.

Ongoing Research

Several clinical trials are currently exploring new applications and optimizing the use of Methotrexate Disodium:

  • A study is investigating its use in combination with other drugs for early remission in peripheral spondyloarthritis[3]
  • Another trial is examining its efficacy in combination with adalimumab for non-infectious uveitis[5]
  • Researchers are also studying optimized dosing strategies for primary CNS lymphoma[4]

These ongoing studies aim to improve treatment outcomes and patient quality of life across various conditions.

Aspect Details
Medical Conditions Studied Psoriatic arthritis, Non-infectious uveitis, Primary central nervous system lymphoma, Peripheral spondyloarthritis
Administration Methods Oral tablets, Subcutaneous injections, Intravenous infusions
Combination Therapies Adalimumab (for uveitis), Various chemotherapy drugs (for PCNSL)
Primary Endpoints Minimal Disease Activity (MDA), Event-free survival, Good Clinical Response
Secondary Endpoints Quality of life, Remission rates, Overall survival, Progression-free survival
Patient Populations Adults (18-75 years), Varying disease severities and treatment histories
Safety Considerations Monitoring for adverse events, Exclusion of patients with certain pre-existing conditions

Ongoing Clinical Trials on Methotrexate Disodium

  • Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

    Recruiting

    3 1 1 1
    Investigated diseases:
    Austria Germany
  • Study of Ruxolitinib and Chemotherapy Drug Combination for Children with Acute Lymphoblastic Leukemia and JAK/STAT Pathway Activation

    Recruiting

    4 1 1 1
    Poland
  • Study on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol

    Recruiting

    3 1 1 1
    Investigated diseases:
    Germany Italy
  • Discontinuation of methotrexate or leflunomide in rheumatoid arthritis patients on TNF inhibitor therapy

    Not yet recruiting

    3 1 1 1
    The Netherlands
  • Study on Peripheral Spondyloarthritis: Comparing Methotrexate Disodium and Golimumab for Early Remission in Adult Patients

    Not recruiting

    3 1 1
    Investigated diseases:
    Belgium
  • Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Austria Germany Italy
  • Study on Methotrexate and Adalimumab for Non-Infectious Uveitis in Patients: Evaluating Effectiveness and Safety

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Spain
  • Study to Predict Tofacitinib Effectiveness in Psoriatic Arthritis Patients Using Tofacitinib, Methotrexate, and Folic Acid

    Not recruiting

    3 1 1 1
    The Netherlands
  • Study on Immunosuppressive Therapies with Asfotase Alfa for Patients with Hypophosphatasia Experiencing Reduced Treatment Effectiveness

    Not recruiting

    3 1 1 1
    Investigated diseases:
    France
  • Study on Acute Lymphoblastic Leukemia Treatment in Children and Adolescents Using Bortezomib, Blinatumomab, and Methotrexate Combination

    Not recruiting

    3 1 1 1
    Poland

Glossary

  • PCNSL: Primary Central Nervous System Lymphoma, a rare type of cancer that affects the brain and spinal cord.
  • Psoriatic arthritis: A form of inflammatory arthritis that affects some people with psoriasis, causing joint pain, stiffness, and swelling.
  • Uveitis: Inflammation of the uvea, the middle layer of the eye, which can cause eye pain, redness, and vision problems.
  • DMARD: Disease-Modifying Antirheumatic Drug, a category of medications used to slow or stop the progression of inflammatory arthritis.
  • Autologous stem cell transplantation: A procedure where a patient's own stem cells are collected, stored, and then reinfused after high-dose chemotherapy to help restore the immune system.
  • Minimal Disease Activity (MDA): A state of low disease activity in psoriatic arthritis, used as a treatment target in clinical practice and research.
  • CASPAR criteria: Classification Criteria for Psoriatic Arthritis, a standardized set of criteria used to diagnose psoriatic arthritis in clinical settings and research.
  • Immunosuppressive therapy: Treatment that suppresses or reduces the strength of the body's immune system, often used to manage autoimmune diseases or prevent organ rejection after transplantation.
  • Biomarker: A measurable indicator of a biological state or condition, often used to predict treatment response or disease progression.
  • Quality of life (QoL): A measure of an individual's overall well-being, including physical, mental, and social aspects, often assessed in clinical trials to evaluate treatment impact.

References

  1. http://clinicaltrials.eu/trial/study-on-immunosuppressive-therapies-with-asfotase-alfa-for-patients-with-hypophosphatasia-experiencing-reduced-treatment-effectiveness/
  2. http://clinicaltrials.eu/trial/study-on-reducing-immunosuppressive-drugs-in-adults-with-psoriatic-arthritis-methotrexate-disodium-abatacept-and-certolizumab-pegol/
  3. http://clinicaltrials.eu/trial/study-on-peripheral-spondyloarthritis-comparing-methotrexate-disodium-and-golimumab-for-early-remission-in-adult-patients/
  4. http://clinicaltrials.eu/trial/study-on-de-escalated-induction-therapy-with-methotrexate-cytarabine-thiotepa-and-rituximab-for-newly-diagnosed-primary-cns-lymphoma-patients/
  5. http://clinicaltrials.eu/trial/study-on-methotrexate-and-adalimumab-for-non-infectious-uveitis-in-patients-evaluating-effectiveness-and-safety/